GLP-1RA pharmacokinetics and clinical effects: focus on cardiac, vascular, and glomerular structures

Abstract

ABSTRACT Introduction Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a key drug class in the management of the cardio-nephro-metabolic continuum. Their effects extend to the cardiac, vascular, and renal systems, providing a pathophysiological basis for the results of cardiovascular outcomes trials. Their pharmacokinetic properties substantially contribute, as structural modifications prolonged plasma half-life and increased systemic exposure through resistance to enzymatic degradation, albumin binding, and optimization of molecular size. Areas covered This review integrates current evidence on pharmacokinetics, pharmacodynamics, and clinical effects of GLP-1RA, focusing on the heart, vascular system, and kidney. A literature search up to March 2026 was performed using MEDLINE, EMBASE, Google Scholar, Web of Science, and the Cochrane Controlled Trials Register. GLP-1RAs exert modest chronotropic effects and provide cardiac protection in ischemia-reperfusion, although direct myocardial effects remain incompletely defined. Vascular benefits appear to be mediated by improved endothelial function, reduced oxidative stress, and modulation of nitric oxide pathways. In the kidney, GLP-1RAs modulate proximal tubular sodium reabsorption and tubuloglomerular feedback, leading to reduced albuminuria and a slower decline in renal function. Clinical trials and meta-analyses have documented reductions in major cardiovascular and renal outcomes. Expert opinion In our view, pharmacokinetics are a major determinant of the clinical profile of GLP‑1RAs, beyond glycemic control alone.